ExpreS2ion Biotechnologies的动态

?? Major breakthrough! The FDA has approved Zihera, a groundbreaking cancer-treating antibody developed by Vancouver-based biotech company Zymeworks! ?? This approval marks a huge milestone for treating metastatic HER2-positive biliary tract cancer—a rare and deadly form of GI cancer. This game-changing treatment offers hope where chemotherapy has failed, showing significant tumor shrinkage in clinical trials. ???? We’re celebrating this success and the incredible innovations coming out of Canada’s biotech sector. ???? Read More: https://lnkd.in/gygUvQw5 #PharmaInnovation #FDAApproval #CancerResearch #Zymeworks #Biotech #TorontoInstituteOfPharmaceuticalTechnology #MedicalBreakthroughs #Her2Positive #HealthTech

The precision of LC-MS/MS is a game-changer in the development of antibody-drug conjugates (ADCs), essential for advancing oncology. By providing a detailed analysis of ADC components, LC-MS/MS ensures that new treatments are effective and safe for patients. Explore how this powerful analytical tool is paving the way for better cancer treatment outcomes. #CancerResearch #LCMS #ADCs #Biotechnology https://hubs.li/Q02GcTHJ0

Aprea is advancing research on #WEE1, a key regulator of DNA damage response. By inhibiting WEE1, our targeted therapeutics disrupt cancer cell repair mechanisms, leading to cell death in tumors with DDR deficiencies. This approach could enhance selectivity, potentially offering safer and more effective treatment options for patients. See here OncLive coverage of a recent poster presentation from the EORTC-NCI-AACR meeting demonstrating Aprea’s progress on this program: https://lnkd.in/exhvMWMa #PrecisionOncology?

Exciting news! Our Business Development team is in Charlotte, North Carolina this week end to attend the AACR special conference on bladder cancer. If you're attending as well, be sure to stop by our booth to learn about how our cutting-edge #MIBC and #NMIBC models for preclinical oncology drug development. See you there! Discover more https://hubs.ly/Q02xFVXb0 #AACR2024 #BladderCancer #OncologyResearch #PreclinicalDrugDevelopment.

Diamond Equity Research: Price Target $0.49 IMU: Receives Orphan Drug Designation for Bile Tract CancerTherapy and Reports Encouraging Blood Cancer Trial Outcomes Read the full Report here: https://lnkd.in/gT2Wis3r #IMU #Imugene #Imugene #AzerCel #CancerResearch #DLBCL #CAR_T #ImmunoOncology #Biotech #ClinicalTrials #CancerTreatment #Oncology #MedicalResearch #equityresearch #equityrelease

Discover the transformative potential of antibody-drug conjugates (ADCs) in targeted cancer therapy. Our latest presentation dives deep into the journey of ADC development, from Paul Ehrlich's early concept of "magic bullets" to their current status as a leading treatment modality. Learn about the intricate bioanalytical challenges, cutting-edge techniques, and regulatory milestones shaping the future of ADCs in oncology. #CancerResearch #ADCs #Bioanalysis #PrecisionMedicine #WuXiAppTec https://hubs.li/Q02zVC290

Excellent overview of ADC target selection from Pythia Bio!

What is a checkpoint inhibitor? Watch as a dive into this immunotherapy agent, a type of drug that helps the immune system attack cancer cells. I'm Dr. Vlad Vitoc, Founder and CEO of MAIA Biotechnology, Inc. bringing you firsthand insights from the #biotech world. #Oncology #OncNews #Immunotherapy

What is a checkpoint inhibitor? In our new CEO spotlight series, Vlad Vitoc, MD, MBA, dives into this drug that helps the immune system attack cancer cells. Find out by watching the video clip below and stay tuned for more as Vlad brings you firsthand insights from the #biotech world. #Oncology #OncNews #Immunotherapy

We announced today that the first patient has been dosed in a Phase 2 clinical trial evaluating CBX-12 in women with platinum-resistant or refractory ovarian cancer who are na?ve to TOP1-targeted therapies. CBX-12 is a first-in-class peptide-drug conjugate (PDC) that uses our proprietary alphalex? technology to enhance the delivery of exatecan, a potent, established TOP1 inhibitor, directly to tumor cells while limiting off-target effects. Learn more at https://bit.ly/4dJDq7S. #biotechnology #oncology #innovation #clinicaltrials